Status:
TERMINATED
AZD2281 in Combination With Liposomal Doxorubicin in Advanced Solid Tumours
Lead Sponsor:
AstraZeneca
Conditions:
Solid Tumors
Eligibility:
All Genders
18-130 years
Phase:
PHASE1
Brief Summary
The study will be an open label, multicenter, dose finding study. Depending on the tolerated dose up to 7 dose levels will be explored in this study, approximately 33 patients (21-54 depending on numb...
Eligibility Criteria
Inclusion
- Histologically or cytologically confirmed metastatic cancer, not amenable to surgery or radiation therapy with curative intent
- Measurable or evaluable disease
- ECOG Performance status 0 - 2
- Estimated life expectancy of at least 12 weeks
Exclusion
- More than 3 prior lines of chemotherapy for advanced disease
- Less than 28 days from active treatment (ie, any treatment used to treat the disease) or high dose radiotherapy (patients may continue concomitant use of stable dose of bisphosphonates if used at least 28 days prior to commencing study treatment and pat
- Prior treatment with \>300mg/m2 cumulative dose of doxorubicin equivalent
- Resistance to anthracyclines defined as progressive disease during anthracycline treatment or within 6 months after the last anthracycline administration.
Key Trial Info
Start Date :
January 5 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 22 2021
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT00819221
Start Date
January 5 2009
End Date
December 22 2021
Last Update
August 30 2022
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Milan, Italy, 20133
2
Research Site
Bellinzona, Switzerland, CH-6500
3
Research Site
Chur, Switzerland, CH-7000